1. Web alert

   News Pages: 85 - 86

2. Cognitive dysfunction in the patient with antiphospholipid antibodies: Considerations for cause and treatment

   • Melanie J. Harrison
   • Lisa D. Ravdin

   OriginalPaper Pages: 89 - 94

3. Prevalence of secondary hematologic disorders in the antiphospholipid syndrome: Impact on coagulation risk

   • Sharon L. Kolasinski

   OriginalPaper Pages: 95 - 99

4. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis

   • Ewa Olech
   • Joan T. Merrill

   OriginalPaper Pages: 100 - 108

5. Do antiphospholipid antibodies develop for a purpose?

   • Joan T. Merrill

   OriginalPaper Pages: 109 - 113

6. Management of the antiphospholipid syndrome

   • Paul DeMarco
   • Inderprit Singh
   • Arthur Weinstein

   OriginalPaper Pages: 114 - 120

7. T cells and B cells in the pathogenesis of systemic sclerosis: Recent insights and therapeutic opportunities

   • Francesco Del Galdo
   • Carol M. Artlett

   OriginalPaper Pages: 123 - 130

8. Microvascular damage in systemic sclerosis: Detection and monitoring with biomarkers

   • Laura K. Hummers

   OriginalPaper Pages: 131 - 137

9. Transforming growth factor-β: Recent advances on its role in immune tolerance

   • Martin A. Kriegel
   • Ming O. Li
   • Richard A. Flavell

   OriginalPaper Pages: 138 - 144

10. The role of circulating fibrocytes in fibrosis

    • Timothy E. Quan
    • Shawn E. Cowper
    • Richard Bucala

    OriginalPaper Pages: 145 - 150

11. Nephrogenic systemic fibrosis: An update

    • Shawn E. Cowper
    • Philip J. Boyer

    OriginalPaper Pages: 151 - 157